Nutriband Inc. (NASDAQ:NTRB – Get Free Report) shares dropped 3.4% on Wednesday . The stock traded as low as $3.41 and last traded at $3.41. Approximately 17,752 shares traded hands during trading, an increase of 84% from the average daily volume of 9,630 shares. The stock had previously closed at $3.53.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings upgraded Nutriband from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, June 3rd. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Reduce”.
Get Our Latest Stock Report on NTRB
Nutriband Stock Performance
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Nutriband stock. Vanguard Group Inc. increased its stake in Nutriband Inc. (NASDAQ:NTRB – Free Report) by 1.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 202,738 shares of the company’s stock after purchasing an additional 3,111 shares during the period. Vanguard Group Inc. owned approximately 1.68% of Nutriband worth $1,429,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 19.70% of the company’s stock.
About Nutriband
Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility.
Featured Stories
- Five stocks we like better than Nutriband
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for Nutriband Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nutriband and related companies with MarketBeat.com's FREE daily email newsletter.
